Stockscreener 앱 받기
19.75
2.92%
0.56
시간 외 거래:
19.75
전일 마감가:
$19.19
열려 있는:
$19.25
하루 거래량:
240.61K
Relative Volume:
0.90
시가총액:
$307.78M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+17.00%
1개월 성능:
+11.27%
6개월 성능:
-13.72%
1년 성능:
-48.65%
1일 변동 폭
$19.08
$21.19
1주일 범위
$14.65
$21.19
52주 변동 폭
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
명칭
Neurogene Inc
전화
(877) 237-5020
주소
535 W 24TH STREET, NEW YORK
NGNE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
19.75 | 307.78M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-16 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2024-03-21 | 개시 | William Blair | Outperform |
| 2024-01-08 | 개시 | H.C. Wainwright | Buy |
| 2024-01-05 | 개시 | Stifel | Buy |
| 2024-01-04 | 개시 | TD Cowen | Outperform |
모두보기
Neurogene Inc 주식(NGNE)의 최신 뉴스
Craig-Hallum bullish on Neurogene, initiates with a Buy - Yahoo Finance
Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at Craig Hallum - Defense World
Neurogene (NGNE) Receives New Buy Rating from Craig-Hallum | NGN - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for - GuruFocus
Neurogene (NGNE) Receives Positive Coverage with a $50 Price Tar - GuruFocus
Neurogene (NGNE) Gains Attention with Promising Gene Therapy for Rett Syndrome | NGNE Stock News - GuruFocus
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Investing.com Nigeria
BMO Capital Markets Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene’s (NGNE) Outperform Rating Reaffirmed at BMO Capital Markets - Defense World
Neurogene (NGNE) Price Target Raised by BMO Capital | NGNE Stock News - GuruFocus
Neurogene Approves Amendments at Annual Stockholders Meeting - TipRanks
Neurogene price target raised to $26 from $22 at BMO Capital - Investing.com Canada
Neurogene Inc. (NASDAQ:NGNE) Receives $44.60 Consensus PT from Brokerages - Defense World
Two Sigma Investments LP Invests $472,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Highlights Gene Therapy Advancements in New Update - TipRanks
Neurogene Inc. (NASDAQ:NGNE) Stock Position Lifted by Wellington Management Group LLP - Defense World
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
Squarepoint Ops LLC Has $398,000 Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World
BNP Paribas Financial Markets Cuts Stake in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Reports Q1 2025 Financial Progress and Updates - TipRanks
Northern Trust Corp Buys 5,845 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
BMO Capital Markets Forecasts Strong Price Appreciation for Neurogene (NASDAQ:NGNE) Stock - Defense World
Deutsche Bank AG Sells 181,997 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene (NGNE) Receives Price Target Boost from BMO Capital | - GuruFocus
Neurogene (NGNE) Receives Price Target Boost from BMO Capital | NGNE Stock News - GuruFocus
Neurogene stock target raised to $22 by BMO Capital - Investing.com Nigeria
ASGCT Roundup: Sarepta, Rocket, Neurogene and the World’s First Tailored CRISPR Therapy - NewsBreak: Local News & Alerts
Neurogene introduces gene therapy monitoring system after patient death - Yahoo Finance
Neurogene (NASDAQ:NGNE) Stock Rating Lowered by Robert W. Baird - Defense World
Baird R W Downgrades Neurogene (NASDAQ:NGNE) to Hold - Defense World
Neurogene presents HLH treatment strategy at ASGCT meeting By Investing.com - Investing.com Nigeria
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.20 - Defense World
Neurogene Shares Drop After Downgrade From Baird - marketscreener.com
This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga
Neurogene stock downgraded at Baird (NGNE:NASDAQ) - Seeking Alpha
Neurogene (NGNE) Downgraded to Neutral with Lowered Price Target | NGNE Stock News - GuruFocus
Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy - GuruFocus
Neurogene presents HLH treatment strategy at ASGCT meeting - Investing.com Australia
Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav - marketscreener.com
Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy Complication | NGNE Stock News - GuruFocus
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Eagle-Tribune
Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | - GuruFocus
Baird cuts Neurogene stock rating, lowers price target to $24 By Investing.com - Investing.com Nigeria
Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | NGNE Stock News - GuruFocus
Baird cuts Neurogene stock rating, lowers price target to $24 - Investing.com
Q2 Earnings Estimate for Neurogene Issued By HC Wainwright - Defense World
Rett Syndrome treatment Market Is Booming Worldwide 2025-2032 | - openPR.com
HC Wainwright Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene (NGNE) Analyst Rating Update: Target Price Adjusted | - GuruFocus
Neurogene (NGNE) Target Price Reduced, Buy Rating Maintained | N - GuruFocus
Neurogene Inc (NGNE) 재무 분석
Neurogene Inc (NGNE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):